Literature DB >> 23089278

Advanced kidney failure and hyperuricemia.

Mariana Murea1.   

Abstract

Metabolic end products accumulate in kidney failure, including uric acid (UA), a terminal product of purine catabolism. Hyperuricemia (HUA) can cause gout and has been increasingly linked with cardiovascular (CV) morbidity and mortality, outcomes that are highly prevalent in patients with kidney disease. Serum UA levels rise as glomerular filtration declines, whereas the frequency of gouty attacks declines and the incidence of CV death rises precipitously. Herein, we review the kinetics of UA metabolism in CKD and dialysis and discuss the possible mechanisms of gout mitigation in kidney failure and the potential contribution of hyperuricemic milieu to CV outcomes in patients with kidney disease.
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089278     DOI: 10.1053/j.ackd.2012.07.008

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  10 in total

1.  Identification of microRNAs and their target genes in Alport syndrome using deep sequencing of iPSCs samples.

Authors:  Wen-biao Chen; Jian-rong Huang; Xiang-qi Yu; Xiao-cong Lin; Yong Dai
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

2.  Study on the Risk Factors for Hyperuricaemia and Related Vascular Complications in Patients with Type 2 Diabetes Mellitus.

Authors:  Rong Shi; Zheyun Niu; Birong Wu; Fan Hu
Journal:  Risk Manag Healthc Policy       Date:  2020-09-21

3.  Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis.

Authors:  Yili Xu; Jiayu Zhu; Li Gao; Yun Liu; Jie Shen; Chong Shen; Glenn Matfin; Xiaohong Wu
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

4.  Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats.

Authors:  Yansheng Wu; Fei He; Yingqiao Li; Huiling Wang; Liqiang Shi; Qiang Wan; Jiaoying Ou; Xiaoying Zhang; Di Huang; Lin Xu; Pinglan Lin; Guanghui Yang; Liqun He; Jiandong Gao
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-12       Impact factor: 2.629

5.  Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study.

Authors:  Arun Kumar A U; Leonard D Browne; Xia Li; Fahd Adeeb; Fernando Perez-Ruiz; Alexander D Fraser; Austin G Stack
Journal:  PLoS One       Date:  2018-05-31       Impact factor: 3.240

6.  Febuxostat for hyperuricemia in patients with advanced chronic kidney disease.

Authors:  Tetsu Akimoto; Yoshiyuki Morishita; Chiharu Ito; Osamu Iimura; Sadao Tsunematsu; Yuko Watanabe; Eiji Kusano; Daisuke Nagata
Journal:  Drug Target Insights       Date:  2014-08-13

7.  Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient.

Authors:  Lynda Ann Frassetto; Suzanne Gibson
Journal:  Case Rep Nephrol       Date:  2016-04-21

8.  Roles of peritoneal clearance and residual kidney removal in control of uric acid in patients on peritoneal dialysis.

Authors:  Xi Xiao; Hongjian Ye; Chunyan Yi; Jianxiong Lin; Yuan Peng; Xuan Huang; Meiju Wu; Haishan Wu; Haiping Mao; Xueqing Yu; Xiao Yang
Journal:  BMC Nephrol       Date:  2020-04-25       Impact factor: 2.388

9.  Nonadherence of Oral Antihyperglycemic Medication Will Increase Risk of End-Stage Renal Disease.

Authors:  Po-Ya Chang; Li-Nien Chien; Yuh-Feng Lin; Hung-Yi Chiou; Wen-Ta Chiu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

10.  Ameliorative effect and mechanism of Yi-Suan-Cha against hyperuricemia in rats.

Authors:  Yuanyuan Qin; Xuan Zhang; Hui Tao; Yangyang Wu; Jie Yan; Lin Liao; Jianjun Meng; Faquan Lin
Journal:  J Clin Lab Anal       Date:  2021-07-12       Impact factor: 2.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.